ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome

Recruiting now · Phase 1/Phase 2

Conditions studied: Dravet Syndrome

In brief

The primary purpose of this study is to evaluate the safety and tolerability of ION337 in participants with Dravet syndrome (DS).

Key facts

Study ID

NCT07531745

Run by

Ionis Pharmaceuticals, Inc.

People needed

32

Starts

2026-05-21

Expected to finish

2030-12-01

Last updated by the study team

2026-08-05

Who can join

Age: 2 and older, up to 12. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Michigan Health System — Ann Arbor, Michigan, United States (enrolling)
• Mayo Clinic — Rochester, Minnesota, United States (enrolling)
• Le Bonheur Children's Hospital — Memphis, Tennessee, United States (enrolling)
• Seattle Children's Hospital — Seattle, Washington, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.